Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
76-week open-label extension study of canakinumab in active rheumatoid arthritis
2007-000491-16Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in rheumatoid arthritis (RA), sponsored by Novartis. Primary endpoints: Long-term safety and tolerability of canakinumab, ACR50 response and 3 more. Started Mar 2007; status: completed.
02
Drugs
canakinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-000491-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000491-16.